Template:DM outpatient managment: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
===[[Diabetes]] Outpatient Management=== | ===[[Diabetes]] Outpatient Management=== | ||
*1st line [[Metformin]] 500mg BID --> 1000mg BID, do not give in people with abnormal LFT's, CHF Stage 3/4 and ARI, CKD | *1st line: [[Metformin]] 500mg BID --> 1000mg BID, do not give in people with abnormal LFT's, CHF Stage 3/4 and ARI, CKD | ||
*2nd Agent [[Glipizide]] start 2.5mg BID -->5mg BID, need to monitor for hypoglycemia | *2nd Agent: [[Glipizide]] start 2.5mg BID -->5mg BID, need to monitor for hypoglycemia | ||
*3rd Agent [[Pioglitazone]] | *3rd Agent: [[Pioglitazone]] | ||
*After 3 agents need to start [[insulin]] if not controlled | *After 3 agents: need to start [[insulin]] if not controlled | ||
**NPH BID or Lantus Qday (0.5mg/kg) and titrate to Fasting Blood Sugar | **NPH BID or Lantus Qday (0.5mg/kg) and titrate to Fasting Blood Sugar | ||
Revision as of 11:46, 18 January 2017
Diabetes Outpatient Management
- 1st line: Metformin 500mg BID --> 1000mg BID, do not give in people with abnormal LFT's, CHF Stage 3/4 and ARI, CKD
- 2nd Agent: Glipizide start 2.5mg BID -->5mg BID, need to monitor for hypoglycemia
- 3rd Agent: Pioglitazone
- After 3 agents: need to start insulin if not controlled
- NPH BID or Lantus Qday (0.5mg/kg) and titrate to Fasting Blood Sugar